Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Uploaded on Apr 10, 2014
Jason A. Chesney, M.D., Ph.D., Associate Professor of Medicine, Pharmacology & Toxicology, Biochemistry, and Molecular Biology, and Deputy Director, James Graham Brown Cancer Center at The University of Louisville, presented the 2014 Theodore Segal Lecture, "Development of a First-In-Class 6-Phosphofructo-2-Kinase (PFKFB3) Inhibitor for Phase I Trial Testing In Advanced Cancer Patients" at University of Louisville Department of Medicine Grand Rounds on April 3, 2014.
The talk focused on understanding the role of glucose metabolism in the development and progression of cancer, learning about the pre-clinical approaches required to conduct phase I trials of novel anti-cancer therapeutics using PFKFB3 inhibitors as an example, and understanding how rational combination strategies of targeted therapies are determined and tested using combination examples for breast cancer and melanoma.
Presented by the U of L Division of Medical Oncology & Hematology.